NasdaqCM:NEOHealthcare
How DOJ Settlement Resolution and New PTEN CDx Launch Will Impact NeoGenomics (NEO) Investors
In June 2026, NeoGenomics finalized a civil settlement with the U.S. Department of Justice, agreeing to pay US$9,813,260 plus interest to resolve an investigation into consulting arrangements, having previously reserved US$11,200,000 for potential liabilities.
Separately, the company launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for PTEN-deficient prostate adenocarcinoma, expanding its role in targeted prostate cancer care.
We’ll now examine how...